<html>
<head>
<META http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>NCT00191100 on 2006_07_21: ClinicalTrials.gov Archive</title>
<link rel="stylesheet" href="/archive/history.css">
<link rel="stylesheet" href="/archive/received.css">
</head>
<body class="received">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="navLinks" class="navLinks"><a href="/archive/NCT00191100">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00191100">&#8593; Current version of this study</a></div><h1>View of NCT00191100 on
  2006_07_21</h1>
<table class="info">
<tr>
<th nowrap>ClinicalTrials Identifier:</th><td>NCT00191100</td>
</tr>
<tr>
<th>Updated:</th><td>2006_07_21</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p>Phase 3 Randomized Comparison of Concurrent Gemcitabine, Cisplatin, and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Cancer of the Cervix Stages IIB to IVA</p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>The purpose of this study is to compare the effectiveness of two methods of treating cancer of the cervix. Half the patients will receive gemcitabine plus cisplatin while undergoing radiation therapy, followed by gemcitabine and cisplatin and the other half will receive cisplatin along with radiation therapy</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p></p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 3</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Treatment</td>
</tr>
<tr>
<th>Study design</th><td>Randomized</td>
</tr>
<tr>
<th>Study design</th><td>Open Label</td>
</tr>
<tr>
<th>Study design</th><td>Active Control</td>
</tr>
<tr>
<th>Study design</th><td>Parallel Assignment</td>
</tr>
<tr>
<th>Study design</th><td>Efficacy Study</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: 
         Overall survival - the expected median overall survival for the experimental arm is 78.6 months.
      </td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: 
         Time to progressive disease
      </td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: 
         Local failure rate.
      </td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: 
         Tumor response rate.
      </td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: 
         Toxicity.
      </td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: 
         - all performed at time of analysis for primary endpoint
      </td>
</tr>
<tr>
<th>Condition</th><td>
         Cancer of Cervix
      </td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: Gemcitabine</div>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: Cisplatin</div>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>
            No longer recruiting
         </td>
</tr>
<tr>
<th>Start date</th><td>
         2002-05
      </td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>Inclusion Criteria:<br> &nbsp;- diagnosed with cancer of cervix<br> &nbsp;- tumor that can be measured<br> &nbsp;- no previous treatment with chemotherapy or radiation for this cancer<br> &nbsp;- able to give written consent<br> &nbsp;- willing and able to participate in the study, both during the active treatment and the follow-up period.<br>
<br>Exclusion Criteria:<br> &nbsp;- impairment such as hearing loss from prior cisplatin therapy<br> &nbsp;- damage to nerves such as being unable to distinguish hot and cold to touch<br> &nbsp;- used other experimental medication in past 30 days<br> &nbsp;- lab test results are not within the limits required for this study<br> &nbsp;- pregnancy or breast-feeding or possibility of becoming pregnant during this study and not using an approved method of birth control.</p>
</td>
</tr>
<tr>
<th>Gender</th><td>
            Female
         </td>
</tr>
<tr>
<th>Minimum age</th><td>18 Years</td>
</tr>
<tr>
<th>Maximum age</th><td>70 Years</td>
</tr>
<tr>
<th>Healthy volunteers</th><td>No</td>
</tr>
<tr>
<th>Expected enrollment</th><td>500</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>Eli Lilly and Company</td>
</tr>
<tr>
<th>Organization study ID</th><td>4015</td>
</tr>
<tr>
<th>Secondary ID</th><td>
            B9E-MC-JHQS
         </td>
</tr>
<tr>
<th>Sponsor</th><td>
               Eli Lilly and Company
            </td>
</tr>
<tr>
<th>Health Authority</th><td>
               Mexico: National Institute of Public Health, Health Secretariat
         </td>
</tr>
</table><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div></body>
</html>
